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To date, the concerns of men at risk of inheriting a BRCA1 mutation or a BRCA2 mutation have received little
attention. It had been anticipated that few men would be interested in predictive testing when a BRCA mutation
was identified in their family. However, these men are often affected emotionally by diagnoses of breast cancer in
their relatives and may themselves harbor fears that cancer will develop. Male carriers of BRCA1/2 mutations are
at increased risk of development of cancers of several types, including those of the breast and prostate.We conducted
an evaluation of the needs and experiences of 59 male carriers of BRCA1/2 mutations followed at either the
University of Toronto or Creighton University. We assessed their motivations for seeking genetic counseling and
testing, involvement in family discussions of breast and ovarian cancer, risk perception, changes in cancer-screening
practices, and overall satisfaction with the genetic-counseling process. The principal motivation for seeking genetic
counseling was concern for their daughters. The majority (88%) of men participated in family conversations about
breast and ovarian cancer, and 47% participated in conversations about prophylactic surgery. Most men believed
that they were at increased risk of development of cancer (prostate, breast, colorectal, and skin cancers). However,
fewer than one-half (43%) of the men with no previous diagnosis of cancer stated that their prostate can-
cer–surveillance practices had changed after they had received genetic test results. More than one-half (55%) had
intrusive thoughts about their cancer risk. Although levels of satisfaction were high, practitioners should be aware
of (a) potential pressures influencing men to request predictive testing, (b) the difficulties that men encounter in
establishing surveillance regimens for breast and prostate cancer, and (c) the general lack of information about
men’s particular experiences in the medical community.
Introduction
In Canada and the United States, genetic counseling is
available to individuals at increased risk of breast and
ovarian cancer. These individuals usually have a family
history of cancer and may be offered screening for
BRCA1 (MIM 113705) and BRCA2 (MIM 600185)
mutations. Once a mutation has been identified in the
family, predictive genetic testing may be offered to at-
risk relatives, including males. Estimates of the cumu-
lative lifetime risk, to age 70 years, of development of
breast cancer associated with a BRCA1/2 mutation are
28%–87% in females (Ford et al. 1994; Hopper et al.
1999; Warner et al. 1999), and the risk of development
of ovarian cancer is 16%–60% (Ford et al. 1994;
Struewing et al. 1997). Although females face greater
risks, male carriers of BRCA1/2 mutations have an el-
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evated risk of development of breast, prostate, and other
cancers (Ford et al. 1994; Struewing et al. 1997; Breast
Cancer Linkage Consortium 1999). Germline BRCA1/2
mutations have been associated, in both sexes, with el-
evated risks for cancers at multiple organ sites, including
colon/rectum, pancreas, gall bladder, bile duct, and
stomach cancers and cutaneous malignant melanoma
(Ford et al. 1994; Breast Cancer Linkage Consortium
1999; Moslehi et al. 2000).
The experiences of patients undergoing genetic testing
for breast and ovarian cancer have been examined
(Kelly 1992; Bleiker et al. 1997; Audrain et al. 1998;
Stadler and Mulvihill 1998; Lynch et al. 1999). Most
studies are based on hypothetical scenarios about an-
ticipated feelings and behaviors among clients prior to
genetic testing. To date, attention has focused on the
women in these families, because they are at greater risk
of development of cancer; little is known about the im-
pact of genetic testing on men who receive a positive
result.
Concern has been expressed over possible adverse
psychological effects of BRCA genetic testing, partic-
ularly for those who receive a positive result. This con-
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cern has prompted a number of investigators to study
predictors of adverse psychological effects—and poten-
tial means of minimizing them (Biesecker et al. 1993;
Hoskins et al. 1995; Richards et al. 1995; Botkin et al.
1996; Lerman et al. 1996, 1997a, 1997b, 1997c, 1998;
Dudok deWit et al. 1998). Only two family-based stud-
ies have examined the reactions of men who received
test results (Lynch et al. 1997; Smith et al. 1999). Smith
et al. (1999) observed that male carriers of mutations
experienced greater distress if they were the first of their
siblings to be tested.
In the present article, we present data on 59 male
carriers of BRCA1/2 mutations who were asked about
their motivations for testing, their involvement in family
discussions of breast and ovarian cancer, their changes
in cancer-screening practices, and their overall satisfac-
tion with the genetic-counseling process. To date, this
is the largest sample of male carriers ofBRCAmutations
who have undergone genetic counseling and testing. The
purpose of this study was to identify unmet needs and
to describe men’s experiences with genetic counseling
and testing and to compare this information with the
experience of the female carriers of BRCAmutations in
these families.
Subjects and Methods
Study Population
Eligible subjects were identified from the familial
breast and ovarian cancer clinics of the Sunnybrook and
Women’s College Health Sciences Centre (Women’s Col-
lege Hospital Campus) of the University of Toronto and
of Creighton University in Omaha. Patients were those
who, during the period June 1995–July 1999 (mean
September 1997), had received a positive result for
BRCA1/2 mutation. Eligible subjects included men who
had received genetic counseling and testing and who had
been found to have a BRCA1/2 mutation. BRCA1/2
mutations were believed to be deleterious and resulted
in a truncated protein.
Sixty-nine subjects (53 from Creighton University and
16 from the University of Toronto) were identified.
Questionnaires were mailed during April–October 1999.
The mean time from disclosure to questionnaire com-
pletion was 2.2 years. Two of the men identified were
later excluded (one was deceased, and one was elderly
and had hearing loss). From the remaining 67 eligible
men, 44 questionnaires were returned by mail. An ad-
ditional 15 (25%) of the men completed the question-
naire by telephone interview conducted by a research
assistant from the University of Toronto. In total, 59
questionnaires were available for analysis—15 from the
Women’s College Hospital in Toronto and 44 from
Creighton University.
Genetic-Counseling Services
Genetic counseling is offered atWomen’s CollegeHos-
pital of the University of Toronto and at Creighton Uni-
versity as a clinical service and within a research pro-
gram. Genetic counseling includes consultation with
either a genetic counselor or an oncology nurse and with
either a geneticist or an oncologist. All available man-
agement options for the consultand and his or her rel-
atives are routinely discussed, including screening, pro-
phylactic surgery, and chemoprevention. Genetic coun-
selors and nurses are responsible for arrangement of re-
ferrals to other specialists, for consultation and screen-
ing. Men and women in these familial cancer programs
are provided with a minimum of one pretest counseling
session and one disclosure counseling session.
Procedures
All study procedures were approved by the Institu-
tional Review Boards of Women’s College Hospital in
Toronto and of Creighton University. Eligible men re-
ceived a letter explaining the study, an invitation to par-
ticipate that was accompanied by a notice that they
might be contacted by telephone, a consent form, and
a questionnaire. If a man wished to participate, he re-
turned the completed questionnaire to the investigators.
Men who did not return their questionnaire were con-
tacted by telephone and were asked to participate by
telephone interview.
Questionnaire Design
The questionnaire consisted of 40 items assessing pa-
tients’ motivations for seeking genetic services, infor-
mation needs, screening practices, emotional reactions,
access to services (i.e., health-care referrals), support re-
sources, desire to take part in a support group, and over-
all experience in genetic counseling. The majority of
questions were of the multiple-response type, with ad-
ditional space for the respondents to explain their an-
swer choices. Open-ended questions related to clients’
opinions or emotional reactions. The questionnaire is
based on a questionnaire designed for female carriers of
mutations and described elsewhere (Metcalfe et al.
2000). These questionnaires are available on request.
Analysis
Data analysis was performed by SPSS statistical pack-
age 10.0. Responses were divided between unaffected
men and those with a previous diagnosis of cancer. Ed-
ucation levels were divided into two groups: (1) high
school graduation or less and (2) more than high school.
Age was analyzed as a continuous variable and as a
categorical variable. When it was analyzed as a cate-
gorical variable, subjects were divided into two groups:
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Table 2
Characteristics of Mothers and Daughters of Male Carriers of
BRCA1/2 Mutations
BRCA1 BRCA2
TOTALNo. of Subjects
Mothers:
Breast cancer 9 8 29%
Ovarian cancer 12 20%
Breast cancer and ovarian cancer 3 5%
Died because of either breast
cancer or ovarian cancer 23 3 44%
Daughters:
Breast cancer 4 4 14%
Ovarian cancer 1 2%
Breast cancer and ovarian cancer 1 2%
Died because of either breast
cancer or ovarian cancer 1 1 3%
Mean Age
at Diagnosis
(years)
Mothers 45.3 52.6
Daughters 33.7 38.2
Table 1
Cancer Sites Reported among 12 Male Carriers
of BRCA1/2 Mutations
CANCER
NO. OF SITES
REPORTED
AGE(S) AT
DIAGNOSIS
(years)
BRCA1
( )np 41
BRCA2
( )np 18
Prostate 1 76
Colon 2 65, 76
Breast 1 2 53, 58, 70
Testicular 1 44
Melanoma 1 1 36, 46
Basal cell 1 1 38, 50
Sarcoma 1 33
Overall 6 (15%) 6 (33%) 53.8
those !50 years of age and those50 years of age. Either
Pearson’s x2 test or Fisher’s exact test was used for nom-
inal data, and Student’s t-tests were used for comparison
of continuous variables. The significance level was set
at .05 (two sided).
Results
Study Subjects
Sixty-seven male carriers of BRCA mutations were
eligible. The overall response rate was 88%, and 59
questionnaires were available for analysis. Fifteen re-
spondents participated by telephone interview. Four
men did not return the questionnaire (no contact was
possible by telephone); three men were lost to follow-
up, and one man refused to participate. The 59 re-
spondents were from 31 different families. Forty-one
men were carriers of BRCA1 mutations, and 18 were
carriers of BRCA2 mutations. Twelve men (20%) had
a previous diagnosis of cancer (table 1). All subjects
were white and of either Ashkenazi Jewish or other
European descent, except for one man of Pakistani or-
igin. The mean age of the respondents was 53.8 years
(range 26–83 years); 49% of men were age !50 years,
and four men were age 175 years. More than one-half
of the men had a mother diagnosed with either breast
cancer or ovarian cancer. The majority (78%) of the
men had one or more daughters; 25 men had one
daughter, eight men had two daughters, 9 had three
daughters, and 4 had four daughters. The mean age of
the daughters was 26.2 years. Ten men (17%) had a
daughter who had been diagnosed with either premen-
opausal breast cancer or ovarian cancer. The charac-
teristics of mothers and daughters of the men are given
in table 2. The majority (43/59) of respondents had
some postsecondary education. Thirty-three men
(56%) had received either a college or technical school
diploma (12/59) or a university degree (21/59).
Reasons for Seeking Genetic Counseling
Approximately one-half of the men stated that the
primary reason for seeking genetic counseling was con-
cern for their families (14/59) or children (16/59), in
particular for their daughters (fig. 1). Ten men indicated
that their primary motivation for seeking genetic coun-
seling was to learn about their own personal risk for
cancer; 16 men cited this as a secondary reason. No
significant associations were observed between motiva-
tions for testing and cancer status ( ), age (Pp .56 Pp
), education ( ), or daughter’s cancer status.27 Pp .21
( ). Four men cited their primary reason for seek-Pp .12
ing genetic testing as being “my family’s recommenda-
tion.” When asked who had referred them for genetic
counseling, the majority (49/59) of men responded that
a family member had referred them. Forty-one men
(70%) had a female relative (sister, cousin, mother,
daughter, niece, or aunt) who had initiated the genetic-
counseling process for the family; 11 men (19%) initi-
ated the testing process themselves.
Support Needs
Genetic counselors were cited as the main sources of
psychosocial support (14/59 cases), followed closely by
doctors, spouses, and family members. Only two men
(3%) felt that they needed more support than was re-
ceived. The proportion of men who felt that they needed
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Figure 1 Primary reason for seeking genetic counseling, according to male and female carriers of BRCA1/2mutations. Black bars represent
the percentage of respondents among female carriers of BRCA1/2 mutations ( ); white bars represent the percentage of male carriers ofnp 79
BRCA1/2 mutations ( ). Significant differences were observed between male and female respondents, for personal risk, children’s risk,np 59
and family’s risk as the primary motivations for seeking genetic counseling and testing. Asterisks (*) indicate that Pearson’s x2 betweenPp .015
three categories and that Fisher’s exact between two categories (the categories of “children” and “family” were combined).Pp .005
more support showed no significant differences within
any category—cancer status ( ), age ( ),Pp .46 Pp .92
education ( ), whether they had daughtersPp .66
( ), and daughter’s cancer status ( ). EightPp .62 Pp .86
men felt that they needed an appointment for counseling
after the disclosure of test results. Three men requested
referrals to other health-care professionals who were
knowledgeable about breast cancer genetics. Fifty-three
percent (29/55) felt that a support group was necessary
for both male and female carriers of BRCA mutations,
and 63% (33/52) of the men indicated that a support
group was particularly necessary for female carriers of
mutations. Twenty-nine percent (16/55) expressed in-
terest in participating in a support group specifically for
male carriers of mutations. Topics recommended for dis-
cussion included how to communicate information to
family members, the general perception that breast can-
cer is not a man’s disease, and advice on lifestyle mod-
ifications designed to reduce cancer risk.
Risk Perception
The majority (36/45) of unaffected men (i.e., those
with no previous diagnosis of cancer) believed that they
were at increased risk of development of cancer. Two
men believed that they were at significantly increased
risk of development of cancers related to their occupa-
tion (firefighting and farming). The nine men who be-
lieved that they were not at increased risk of develop-
ment of cancer were all unaffected. Two men with a
previous history of cancer stated that they were at in-
creased risk of development of all types of cancer. More
than one-half (52%) of the respondents indicated that
they had an increased susceptibility to prostate cancer.
One-third of male carriers of BRCA2 mutations speci-
fied increased susceptibility to breast cancer, whereas
22% of male carriers of BRCA1 mutations specified in-
creased susceptibility to colorectal cancer. The organ
sites specified by the unaffected men are shown in figure
2. No significant differences in risk perception were ob-
served within any category—cancer status ( ),Pp .18
age ( ), education ( ), whether the menPp .76 Pp .23
had daughters ( ), and daughter’s cancer statusPp .32
( ). However, 97% (29/30) of men who had aPp .44
mother diagnosed with either breast cancer or ovarian
cancer stated that they were themselves at increased risk
of development of cancer, compared with 70% of men
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Table 3
Risk Perception among 47 Unaffected Male Carriers of BRCA1/2
Mutations
CHARACTERISTIC
NO. OF SUBJECTS
TOTALBRCA1 BRCA2
Risk perception:
Not at risk 7 2 20%
Elevated risk 26 10 80%
Intrusive thoughts:
Absent 17 7 52%
Present: 17 5 48%
Daily 1 1 4%
Regularly 2 1 7%
Sometimes or randomly 3 7%
Monthly 1 1 4%
Annually (“on my birthday”) 1 2%
Rarely 6 1 15%
Not sure 1 1 4%
Figure 2 Percentage of male carriers of BRCA1/2 mutations who reported risk of development of specific cancers (cumulative responses).
Black bars represent the percentage of male carriers of BRCA2 mutations ( ); white bars represent the percentage of carriers of BRCA1np 18
mutations ( ).np 41
without an affected mother ( ). Similarly, 96%Pp .007
(23/24) of men who had had a mother die of either breast
cancer or ovarian cancer stated that they were at in-
creased risk of development of cancer. Fifty-five percent
of the men indicated that they had intrusive thoughts
about their increased risk of development of cancer, in-
cluding nearly one-half of the unaffected men (table 3).
Surveillance Practices
Most (41/58) male carriers of mutations believed that
they were receiving adequate care for the prevention of
prostate cancer. Nine men (16%) felt that they had not
received enough information about cancer surveillance.
Six men remarked on their own delay in implementing
a consistent surveillance regimen. One man from the
United States felt that, because of health-insurance cov-
erage limitations, he was not receiving adequate medical
care. The majority of male carriers of mutations thought
that genetic counseling provided them with adequate
information about screening (85%) and about risk of
development of breast and/or ovarian cancer in their
female relatives (88%). Only 43% of all unaffected men
reported that they had altered their cancer-surveillance
programs after learning of the results of screening. Al-
teration of cancer-screening practices in unaffected men
was not dependent on age ( ) or educationPp .25
( ). The screening practices of the men prior toPp .11
receipt of genetic-test results was not known.
Adherence to recommendations following prostate
cancer screening with prostate-specific antigen (PSA)
was reported by approximately one-half of the men. The
majority (78%) of the men who underwent PSA testing
reported being screened on an annual basis. Digital rectal
examination (DRE) was reported by a similar number
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Table 4
Surveillance Practices among 47 Unaffected Male Carriers of
BRCA1/2 Mutations
SURVEILLANCE PRACTICE
NO. OF SUBJECTS
TOTALBRCA1 BRCA2
Since learning of result:
Not changed 16 9 53%
Changed 18 2 43%
To be arranged 1 1 4%
Frequency:
PSA:
Ever 19 6 56%
Semiannually 1 2%
Annually 11 6 36%
Biannually 3 6%
To be arranged 3 1 9%
DRE:
Ever 19 6 53%
Semiannually 2 4%
Annually 9 4 28%
Biannually 2 1 6%
To be arranged 3 1 9%
Clinical breast examination
Ever 1 4 11%
Semiannually 1 1 4%
Annually 3 6%
Breast self-examination:
Ever 3 4 15%
Rarely 1 1 4%
Monthly 1 1 4%
Twice monthly 2 4%
Weekly 1 2%
Colonoscopy, ever 3 6%
Fecal occult blood, ever 2 4%
Skin examination, annually 1 1 4%
Physical examination, annually 2 4%
(59%) of carriers of mutations. Men50 years old were
more likely to have undergone PSA screening than were
men !50 years old ( ), whereas this age effectP ! .0001
was not significant for DRE ( ). Six men indi-Pp .084
cated that they had experienced difficulties in setting up
a prostate cancer–surveillance regimen with their phy-
sician: “My urologist says PSA doesn’t tell you any-
thing”; “I was told it was not necessary for men under
50”; “My doctor was reluctant because of my (older)
age.” Table 4 summarizes the surveillance practices of
the men with no previous cancer diagnosis. Respondents
were requested to provide the date of their last visit for
PSA and DRE. The mean date of last PSAwas September
1998 (range 1997–2000), whereas the mean date of last
DRE was April 1998 (range 1994–2000). When com-
pared with the mean date of questionnaire completion
(December 1999 [range June 1999–June 2000]), these
dates suggest that male carriers of mutations are indeed
attempting to maintain annual PSA screening for pros-
tate cancer, although DRE appears to be scheduled
slightly less regularly.
All three men with a previous breast cancer diagnosis
reported having had clinical breast examinations and
having performed regular breast self-examinations. Two
affected men performed self-examinations on a daily ba-
sis (i.e., “every time I shower”). In contrast, only seven
men (15%) with no previous diagnosis of cancer per-
formed breast self-examinations, including four carriers
(25%) of BRCA2 mutations (table 4). Thirteen men
(22%) specified that they either were involved in other
cancer-screening programs, such as those for colorectal
cancer or skin cancer, or had an annual physical ex-
amination with their general practitioner.
Emotional Responses
The men expressed a variety of reactions to their pos-
itive result (table 5), including relief of anxiety when
uncertainty about risk status was removed (2/59), con-
cerns about personal cancer risk (5/59), disappointment
(6/59), and feelings of sadness (2/59) or fear (3/59) (table
5). Almost one-quarter (14/59) of the men felt that the
genetic testing confirmed what they had always sus-
pected. For nine men with daughters, the concern was
immediately transferred: “This means my daughter
needs to be tested.” Two men with daughters experi-
enced guilt as a consequence of learning their carrier
status. One man described how he felt a renewed sym-
pathy and understanding for his sisters who had tested
positive, and he commented on how his riskwasminimal
in comparison.
Discussions with Relatives
The great majority (56/59) of men discussed their ge-
netic-test result with a family member. Five men indi-
cated that they would have liked assistance in sharing
with their families the information about genetic testing.
Only two men wished that their families had involved
them more in the initial genetic-testing process, and 12
(21%) respondents stated that they wished that their
families would be more involved in the genetic-testing
process. The majority (52/59) of men had been included
in past family discussions of risk of development of
breast and/or ovarian cancer. Less than half (28/59) of
the men participated in conversations about prophylac-
tic surgery for reduction of risk of development of breast
and/or ovarian cancer. Ten men stated that their family
relationships had changed since they had received the
results of their BRCA test. The majority (7/10) described
how their family relationships had been strengthened by
this information: “brought family closer,” “heightened
awareness and concern for family members,” “helped
communication in family, greater understanding,” and
“I am more considerate of daughter’s choice to have
preventive surgery.” One man stated that, as a result of
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Table 5
Descriptions of Initial Feelings When Subjects First Received BRCA1/2 Test Result
THEME PARAPHRASED RESPONSE
NO. OF
RESPONSES
NO. OF MEN WITH
Cancer
A Daughter/A
Daughter with Cancera
Family Concern for daughters or children 9 0 9/1
Guilt 2 0 2/1
Concern for sisters 1 0 1/0
Personal risk Concern for self 5 0 2/0
General concern 3 0 1/0
Neutral Not overly concerned 7 0 7/2
Not surprised Confirmed what I’d always suspected 14 3 10/5
Acceptance 5 1 2/0
Relief of anxiety Relief for myself and my family 2 2 2/0
Disappointment 6 0 5/0
Unexpected 1 1 0/0
Anxiety Nervousness, fear, stress 3 1 3/0
Sadness 2 1 1/0
Shock Sense of alarm 3 0 3/0
Existential Sense of mortality 2 0 1/0
Can’t remember 1 1 1/1
a Either breast cancer or ovarian cancer.
his genetic-test result, he is less likely to have additional
children.
Satisfaction with Genetic Counseling
Men were asked to rate their overall satisfaction with
the genetic-counseling process, on a 5-point scale (1 p
extremely dissatisfied; 5 p extremely satisfied). The
mean response for satisfaction was 4.2. All but two re-
spondents indicated that they were at least “satisfied”
with the genetic-counseling process. Four men (7%)
stated that information was missing during their genetic-
counseling appointment at the time of either DNA test-
ing or disclosure of results. The topics specified were risk
of development of colorectal cancer and the health-care
professionals’ limited awareness of male breast cancer.
One man remarked that the genetic counselor should
have included a discussion of both how general practi-
tioners or other physicians may not be aware that men
may get breast cancer and how the male breast is often
neglected during physical examination. This man had
an unsatisfactory experience with his general practi-
tioner after he had detected a lump in his breast by self-
examination. Men 150 years old were more likely than
younger men to say that information was missing from
the genetic-counseling session ( ). There werePp .045
no differences in the need for additional information
based on cancer status ( ), education ( ),Pp .13 Pp .97
whether the men had daughters ( ), or the daugh-Pp .26
ter’s cancer status ( ).Pp .11
Two men from the United States expressed concerns
about insurance implications, both for themselves and
for their children. One man was thankful but thought
that the counseling itself was excessive. Two men (3%)
were not sure whether they would recommend genetic
testing to other men in their situation, and twomen (3%)
would not recommend testing. For the 54 men who
would recommend predictive testing to other men in
their situation, there were two main reasons or themes
for the recommendation—namely, awareness and family
(“to be aware and take necessary precautions,” “knowl-
edge is power,” “important for men with daughters,”
and “to inform offspring of their situation”).
Comparison with Female Carriers of BRCA Mutations
We compared data on male respondents ( )np 59
with those on female carriers of BRCA mutations
( ); the study on female carriers of mutations hasnp 79
been described in detail elsewhere (Metcalfe et al. 2000).
Male carriers of mutations were less likely to have had
a previous diagnosis of cancer than were female carriers
of mutations ( ). Men were more likely thanP ! .0001
women to be referred by a family member for genetic
counseling ( ). Figure 1 depicts the primary rea-P ! .0001
sons for seeking genetic counseling, as indicated by male
and female respondents. There was a statistical differ-
ence observed between male and female respondents in
the three most frequently cited motivations ( ).Pp .015
Table 6 compares the responses of male and female car-
riers of mutations, with regard to specific items assessed
during genetic counseling.
Discussion
To date, attention has focused on women in familieswith
BRCA mutations, because they are believed to be at
greater risk of development of cancer. Our study inves-
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Table 6
Comparison of 59 Male and 79 Female Carriers of BRCA1/2 Mutations
Item Assessed in Genetic Counseling Men Women P
More information needed 7% 21% .032
More support needed 3% 19% !.0001
Support group needed 53% 68% .05
Support group for females 69% 68% .38
Personal interest in support group 23% 34% .038
More information on surveillance needed 16% 18% .2
Surveillance practices changed 44% 58% .11
Surveillance practices changed (among unaffected) 43% 81% .002
Mammography or PSA on a regular basis 59% 70% .76
Receiving adequate care in cancer prevention 77% 81% .77
Result was shared with family 95% 95% 1.0
Help needed in sharing information with relatives 9% 15% .3
Wished family was more involved 21% 31% .26
Feelings or psychological state changed 29% 53% .007
Family or personal relationships changed 18% 33% .04
Overall satisfaction (5-point scale) 4.19 4.02 .32b
a For comparison (Pearson’s x2).
b By t-test.
tigated the perspectives of men who underwent genetic
counseling and who were found to be carriers of a germ-
line BRCA1/2 mutation. These men were motivated to
undergo genetic testing and therefore may be better able
to assimilate genetic-risk information than are those
who declined testing. Our study describes the men’s re-
actions 6 mo after receipt of the results of genetic test-
ing, which allows time for the men to adapt to the news
of their positive result.
Dudok deWit et al. (1996) reported on the psycho-
logical findings on four men from families with breast
cancer who had undergone predictive testing and who
had reported difficulties with the genetic-counseling
process. In particular, the men exhibited avoidance be-
haviors and had a tendency to either miss appointments
or withdraw from testing altogether. McAllister et al.
(1998) concluded that men from families with breast
cancer are affected emotionally by their female relatives’
diagnoses of breast cancer and that their level of distress
is associated with the number of daughters.
The reasons that the male carriers of mutations com-
monly cited for seeking genetic counseling were similar
to those that other studies have reported for women
(Lerman et al. 1995; Bleiker et al. 1997; Lynch et al.
1997). However, men’s motivations appear to differ in
priority. More than one-half of the male carriers of
BRCA mutations were tested for the sake of their chil-
dren or family. In contrast, female carriers of mutations
reported that their primary reason for seeking counsel-
ing and testing was to learn about their own risk (Met-
calfe et al. 2000).
Compared with men, women were more likely to re-
port that their family or personal relationships had
changed as a consequence of genetic testing and to feel
that a support group is necessary for carriers of mu-
tations; women were also more likely to want to take
part in a support group. Consistent with the gender
differences in interest in support groups (Fobair 1997)
is the finding that men who were interested in support
groups had several motivations, including a desire for
more information (e.g., strategies for reduction of risk
of development of cancer), because they either felt mis-
understood at home or experienced a sense of loss.
Other topics specified by male carriers of BRCA mu-
tations who were interested in support groups included
the general perception that breast cancer is not a man’s
disease and strategies to communicate risk information
to family members.
Communication with male relatives in families with
BRCAmutations has been described by female relatives
as particularly difficult because the discovery that men
can be predisposed to a “female” disease is counterin-
tuitive (Green et al. 1997). This perception is not limited
to family members; several respondents experienced dif-
ficulties with health-care practitioners in this regard.
Familial cancer clinics may facilitate communication of
risk-management information to general practitioners
who care for male carriers of BRCA mutations. Female
family members are not necessarily well-informed of the
risks to males, and a number of women described frus-
tration in their attempts to explain the situation to their
brothers (Green et al. 1997). Contrary to previous ob-
servations (McAllister et al. 1998), the majority of our
respondents participated in family discussions of breast
and/or ovarian cancer. However, fewer than one-half of
the men participated in family conversations about pro-
phylactic surgery. This may be explained by the inher-
ently gender-specific issues and risk-management con-
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siderations; however, the number of women in each
family who had considered prophylactic surgery was
not available.
The majority of men were referred by a family mem-
ber. It is of concern that four men reported that their
primary reason for seeking genetic testing was “my fam-
ily’s recommendation.” The response may reflect some
degree of coercion. It is important for practitioners in
familial cancer clinics to be aware of potential pres-
sures—either for or against testing—that may exist
within families and to help promote autonomous de-
cisions.
In 1997, early guidelines for carriers of BRCA1/2
mutations stated that there was insufficient evidence to
recommend or discourage prostate cancer screening
(Burke et al. 1997). Since then, several studies have re-
ported that male carriers of BRCA1/2 mutations are at
a significantly increased risk of development of several
types of cancer—in particular, prostate cancer. Prostate
cancer risk is the most consistent finding for male car-
riers of BRCA1/2 mutations in families with cancer,
and the relative-risk range is 3.33–7.33, or an estimat-
ed 16%–35%, to age 65–70 years (Ford et al. 1994;
Struewing et al. 1997; Breast Cancer Linkage Consor-
tium 1999; Moslehi et al. 2000). However, several stud-
ies of the common BRCA mutations in unselected Ash-
kenazi Jewish men with prostate cancer have failed to
confirm an increased risk (Lehrer et al. 1998; Nastiuk
et al. 1999; Vazina et al. 2000). Germline BRCA1 mu-
tations have also been associated with elevated risks of
colorectal, pancreatic, and male breast cancers (Ford et
al. 1994; Borg et al. 2000; Moslehi et al. 2000). Al-
though the risk of male breast cancer is increased for
carriers ofBRCA1mutations, the risk is greater formale
carriers of BRCA2 mutations and is estimated as being
!10% until age 70 years (Easton et al. 1997). There is
also an increased risk of development of pancreatic,
stomach, bile-duct, and gall-bladder cancers and of cu-
taneous malignant melanoma, in both males and fe-
males who harbor BRCA2 mutations (Breast Cancer
Linkage Consortium 1999). Among the 59male carriers
of BRCA mutations, the cancers were breast (3 cases),
colon (2), cutaneous malignant melanoma (2), basal cell
carcinoma (2), prostate (1), testicular (1), and sarcoma
(unspecified type) (1).
The majority of men in this study harbor fears of
development of cancer. These fears were strongly as-
sociated either with diagnosis of breast or ovarian can-
cer in the mother or with the mother’s death. Fifty-five
percent of male carriers of mutations, including almost
one-half of those with no previous cancer diagnosis,
suffered from intrusive thoughts about their risk of de-
velopment of cancer. The major sites of susceptibility
specified were prostate, breast, colon, and skin. Pan-
creatic cancer was not included among these sites. With
the exception of pancreatic cancer, these sites are con-
sistent with the information presented to male carriers
of mutations during genetic counseling at the University
of Toronto and at Creighton University.
Consistent with previous findings for female carriers
of BRCA mutations (Lerman et al. 2000; Metcalfe et
al. 2000), more than one-half of male carriers of mu-
tations did not adhere to the screening guidelines rec-
ommended after disclosure of genetic-test results. More
attention is needed to promote cancer-screening rec-
ommendations—particularly for prostate cancer and
breast cancer—to male carriers of BRCA mutations
who are undergoing genetic counseling.
The most consistent recommendation given to male
carriers of BRCAmutations at the University of Toronto
and Creighton University clinics pertains to prostate
cancer surveillance, with annual PSA and DRE begin-
ning at age 40 years. There is no standard recommen-
dation for breast cancer screening in male carriers of
BRCA mutations, although men are advised to seek
medical evaluation for any breast mass or change (Burke
et al. 1997). At the University of Toronto and Creighton
University familial cancer clinics, breast cancer screen-
ing, consisting of annual or semiannual clinical breast
examinations and monthly breast self-examinations, is
recommended routinely for male carriers of BRCA2
mutations and, recently, has been recommended also for
male carriers of BRCA1 mutations. Nonetheless, only
25% of male carriers of BRCA2mutations have annual
clinical breast examinations or perform breast self-ex-
aminations. Screening mammography is not usually rec-
ommended for males at risk. Tamoxifen is used as an
adjuvant treatment for male breast cancer (as it is for
female breast cancer), on the basis of tumor character-
istics; but tamoxifen has not yet been proposed as a
chemopreventive agent for males, and its use is not rou-
tinely discussed. Similarly, surgical prevention of breast
cancer (i.e., prophylactic mastectomy) is not offered,
because, at the present time, there are no data to support
this type of risk reduction in males. Clinical skin ex-
aminations for the early detection of melanoma are in-
cluded in the discussion of cancer surveillance for fam-
ilies with BRCA2 mutations. Although the data are
inconsistent, families with BRCA1 mutations are in-
formed of the possible risks for colorectal cancer (Ford
et al. 1994), and screening by colonoscopy, at intervals
of 3–5 years, is recommended.
In general, the information provided to male carri-
ers of BRCA mutations during genetic counseling was
felt to be sufficient. Men may have intrusive thoughts
regarding unresolved grief about past and future
losses—and guilt about passing on a potentially lethal
gene to their children. Greater attention may be needed
for male carriers of mutations 150 years old, particu-
larly with regard to surveillance for prostate cancer and
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for breast cancer. Other issues of particular focus would
include insurance considerations and an increase in
awareness by their primary-care physicians. Further
work is necessary to explore the reasons for noncom-
pliance in recommended surveillance for prostate cancer
in male carriers of BRCA mutations.
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